Laboratory biomarkers and immunological modulation of sintilimab in gastric cancer: A meta-analysis focused on tumor markers and T-cell subsets.

IF 1.5 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-09-05 DOI:10.5937/jomb0-59513

Xian Zhang, Qiang Zhao, Huafei Tang, Rui Qin, Ting Tian, Congying Li, Rui Ma

{"title":"Laboratory biomarkers and immunological modulation of sintilimab in gastric cancer: A meta-analysis focused on tumor markers and T-cell subsets.","authors":"Xian Zhang, Qiang Zhao, Huafei Tang, Rui Qin, Ting Tian, Congying Li, Rui Ma","doi":"10.5937/jomb0-59513","DOIUrl":null,"url":null,"abstract":"Background: Sintilimab, a PD-1 inhibitor, has emerged as a promising immunotherapeutic agent in gastric cancer. However, its impact on laboratory-based biochemical markers and immune indicators remains underexplored. This meta-analysis aimed to evaluate the changes in tumor biomarkers and T lymphocyte subsets, alongside clinical outcomes, in patients receiving sintilimab.Methods: A comprehensive literature search of randomized controlled trials (2022-2025) was conducted across CNKI, Wanfang, VIP, and PubMed databases. Primary outcomes included serum tumor markers (CEA, CA199, CA242) and immune parameters (CD4+, CD8+ T-cell subsets). Secondary outcomes were ORR, DCR, OS, PFS, and adverse reactions. RevMan 5.2 was used for meta-analysis.Results: Sixteen studies were included. Sintilimab treatment significantly reduced CEA, CA199, and CA242 levels (P < 0.0001), and favorably modulated immune subsets by increasing CD4+ and decreasing CD8+ cell counts. These biochemical and immunological improvements correlated with higher ORR, DCR, and OS, without increased adverse events (P > 0.05).Conclusions: Sintilimab confers measurable improvements in key laboratory-based tumor and immune biomarkers, supporting its utility in clinical biochemical monitoring and immunotherapy response evaluation for gastric cancer patients. These findings align with the emerging integration of immunotherapy and biochemical diagnostics in oncology.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 6","pages":"1171-1182"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497473/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-59513","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sintilimab, a PD-1 inhibitor, has emerged as a promising immunotherapeutic agent in gastric cancer. However, its impact on laboratory-based biochemical markers and immune indicators remains underexplored. This meta-analysis aimed to evaluate the changes in tumor biomarkers and T lymphocyte subsets, alongside clinical outcomes, in patients receiving sintilimab.

Methods: A comprehensive literature search of randomized controlled trials (2022-2025) was conducted across CNKI, Wanfang, VIP, and PubMed databases. Primary outcomes included serum tumor markers (CEA, CA199, CA242) and immune parameters (CD4+, CD8+ T-cell subsets). Secondary outcomes were ORR, DCR, OS, PFS, and adverse reactions. RevMan 5.2 was used for meta-analysis.

Results: Sixteen studies were included. Sintilimab treatment significantly reduced CEA, CA199, and CA242 levels (P < 0.0001), and favorably modulated immune subsets by increasing CD4+ and decreasing CD8+ cell counts. These biochemical and immunological improvements correlated with higher ORR, DCR, and OS, without increased adverse events (P > 0.05).

Conclusions: Sintilimab confers measurable improvements in key laboratory-based tumor and immune biomarkers, supporting its utility in clinical biochemical monitoring and immunotherapy response evaluation for gastric cancer patients. These findings align with the emerging integration of immunotherapy and biochemical diagnostics in oncology.

Abstract Image

查看原文本刊更多论文

实验室生物标志物和辛替单抗在胃癌中的免疫调节：一项肿瘤标志物和t细胞亚群的荟萃分析。

背景：辛替单抗是一种PD-1抑制剂，已成为一种很有前景的胃癌免疫治疗药物。然而，其对实验室生化标志物和免疫指标的影响仍未得到充分探讨。本荟萃分析旨在评估接受辛替单抗的患者肿瘤生物标志物和T淋巴细胞亚群的变化以及临床结果。方法：综合检索CNKI、万方、VIP和PubMed数据库中随机对照试验（2022-2025）的文献。主要结局包括血清肿瘤标志物（CEA、CA199、CA242）和免疫参数（CD4+、CD8+ t细胞亚群）。次要终点为ORR、DCR、OS、PFS和不良反应。采用RevMan 5.2进行meta分析。结果：纳入16项研究。辛替单抗治疗显著降低CEA、CA199和CA242水平（P < 0.0001），并通过增加CD4+和减少CD8+细胞计数有利地调节免疫亚群。这些生化和免疫改善与更高的ORR、DCR和OS相关，但没有增加不良事件（P < 0.05）。结论：辛替单抗在关键的实验室肿瘤和免疫生物标志物方面具有显著的改善作用，支持其在胃癌患者临床生化监测和免疫治疗反应评估中的应用。这些发现与肿瘤免疫治疗和生化诊断的新兴整合相一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.